Cardlytics (NASDAQ:CDLX) Shares Down 4.4%

Cardlytics, Inc. (NASDAQ:CDLX)’s stock price traded down 4.4% on Thursday . The stock traded as low as $13.80 and last traded at $14.00. 1,460,107 shares traded hands during mid-day trading, a decline of 11% from the average session volume of 1,642,166 shares. The stock had previously closed at $14.64.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “buy” rating and lifted their price objective for the company from $10.00 to $18.00 in a research report on Friday, March 15th. Needham & Company LLC boosted their price target on shares of Cardlytics from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Finally, Lake Street Capital boosted their price target on shares of Cardlytics from $13.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Cardlytics has an average rating of “Hold” and a consensus target price of $13.20.

Cardlytics Stock Performance

The firm’s 50-day moving average price is $8.55 and its two-hundred day moving average price is $9.98. The firm has a market capitalization of $639.15 million, a PE ratio of -4.48 and a beta of 1.36. The company has a quick ratio of 1.31, a current ratio of 1.31 and a debt-to-equity ratio of 1.91.

Insider Buying and Selling at Cardlytics

In other Cardlytics news, major shareholder Clifford Sosin bought 350,000 shares of Cardlytics stock in a transaction on Monday, March 18th. The stock was purchased at an average cost of $13.40 per share, for a total transaction of $4,690,000.00. Following the completion of the purchase, the insider now directly owns 6,023,676 shares of the company’s stock, valued at $80,717,258.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, major shareholder Clifford Sosin acquired 350,000 shares of Cardlytics stock in a transaction dated Monday, March 18th. The stock was acquired at an average cost of $13.40 per share, for a total transaction of $4,690,000.00. Following the completion of the purchase, the insider now owns 6,023,676 shares of the company’s stock, valued at $80,717,258.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Amit Gupta sold 72,658 shares of the business’s stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $6.10, for a total transaction of $443,213.80. Following the completion of the sale, the chief operating officer now owns 102,342 shares of the company’s stock, valued at $624,286.20. The disclosure for this sale can be found here. Insiders sold 136,556 shares of company stock worth $926,492 over the last ninety days. 0.78% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Cardlytics

Several large investors have recently bought and sold shares of the stock. FMR LLC increased its holdings in Cardlytics by 238.4% in the 2nd quarter. FMR LLC now owns 1,428 shares of the company’s stock valued at $32,000 after buying an additional 1,006 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Cardlytics by 220.6% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,405 shares of the company’s stock worth $32,000 after purchasing an additional 2,343 shares during the last quarter. Point72 Middle East FZE bought a new stake in shares of Cardlytics in the 4th quarter worth about $35,000. Point72 Hong Kong Ltd bought a new stake in shares of Cardlytics in the 2nd quarter worth about $38,000. Finally, Comerica Bank bought a new stake in Cardlytics during the 3rd quarter worth about $40,000. 68.10% of the stock is currently owned by institutional investors and hedge funds.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.